Li Ka-shing
Founder and Chairman @ Horizons Ventures
Hong Kong, Hong Kong
Li Ka-shing is a Series A investor at Horizons Ventures in Hong Kong focused on Health Care and Biotechnology. Mr. Li Ka-shing is the richest person of East Asian descent in the world and the 11th richest person in the world with an estimated wealth of US$26 billion (as estimated by Forbes). His primary operating company is Hutchison Whampoa Limited. Mr Li's younger son, Richard, is Chairman of PCCW, one of Asia's leading internet and telecommunications companies. Mr Li Ka-shing is the Chairman of Cheung Kong (Holdings) Limited and Hutchison Whampoa Limited. Cheung Kong (Holdings) Limited is the flagship of the Cheung Kong Group which has business operations in 54 countries around the world and employs about 240,000 staff. In Hong Kong alone, the Group includes nine listed companies with a combined market capitalization of approximately HKD600 billion (30 June 2009). Hutchison Whampoa Limited is a Fortune Global 500 company. Born in 1928 in Chiu Chow, a coastal city in the southeastern part of China, Mr Li fled to Hong Kong with his family to avoid the perils of war. His father suffered from tuberculosis and passed away in Hong Kong. Shouldering the responsibility of looking after the livelihood of the family, Mr Li was forced to leave school before the age of 15 and found a job in a plastics trading company where he labored 16 hours a day. By 1950, his hard work, prudence and his pursuit of excellence had enabled him to start his own company, Cheung Kong Industries. From manufacturing plastics, Mr Li led and developed his company into a leading real estate investment company in Hong Kong that was listed on the Hong Kong Stock Exchange in 1972. Cheung Kong continued to expand by acquiring Hutchison Whampoa and Hongkong Electric Holdings Limited in 1979 and 1985 respectively. Based in Hong Kong, the Cheung Kong Group's businesses encompass such diverse areas as property development and investment, real estate agency and estate management, hotels, telecommunications and e-commerce, finance and investments, retail, ports and related services, energy, infrastructure projects and materials, media, and biotechnology. Mr Li is a strong believer in synergy — the power of combined efforts. This belief is reflected in his naming his company Cheung Kong Holdings after the Yangtze River that flows through China, a great river that aggregates countless streams and tributaries. The Times in the United Kingdom and Ernst & Young UK jointly named Mr Li as the Entrepreneur of the Millennium at the turn of the century. http://www.hutchison-whampoa.com/eng/about/chairman/chairman.htm 30 June 2009
- Total investments:
- 27
- Last investment:
- Lead investor:
- 41%
Last updated:
For AI agents: llms.txt
Industries Li Ka-shing invests in
Stages Li Ka-shing invests in
Countries Li Ka-shing invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $300k–$11M
- Series A
- $20M–$50M
- Series B
- $15M–$50M
Investment Focus
Industry
- Health Care 5 (19%)
- Biotechnology 4 (15%)
- Medical Device 3 (11%)
- Food and Beverage 3 (11%)
- iOS 2 (7%)
Stage
- Series A 5 (19%)
- Series B 5 (19%)
- Seed 4 (15%)
- Series C 3 (11%)
- Series D 2 (7%)
Country
- United States 10 (37%)
- United Kingdom 3 (11%)
- Israel 2 (7%)
- Canada 1 (4%)
- Sweden 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| MioTech is an artificial intelligence platform that empowers investment managers to better serve their clients in a world of complex data. By integrating and analyzing data from all types of sources, MioTech streamlines the entire investment process, creating an ultimate data-driven investing experience. MioTech has offices in Shanghai and HongKong.MioTech is backed by Horizons Ventures, ZhenFund, and prestigious individual investors around the world. | Venture - Series Unknown / Jan 26, 2024 | ||
| Fertilis is a company that makes in vitro fertilization (IVF) less stressful and more successful for patients and clinicians. | $2M / Seed / Jan 11, 2022 | ||
| Catalog is a developer of a data conversion and storage platform used to offer the next generation of digital data archives and computation. Its platform facilitates the encoding of data and information into DNA format and makes it economically attractive to use DNA as the major medium for long-term archival of data that enables customers to storedigital information in DNA molecules. It brings cutting-edge synthetic biology technologies to the world of information storage and computation.The company was founded in 2016 and is headquartered in Boston, Massachusetts. | $35M / Series B / Sep 30, 2021 | ||
| Owlstone Medical focuses on creating breath-based diagnostic tools to enhance early detection of diseases such as cancer and respiratory conditions. The company's Breath Biopsy platform utilizes advanced technology to identify volatile organic compounds in breath, facilitating the discovery of non-invasive biomarkers. | $57.9M / Series D / Sep 07, 2021 | ||
| H2Pro is a renewable energy company that is working on an efficient green hydrogen production method - E-TAC. Its mission is to enable the wide-scale adoption of sustainable hydrogen fuel by introducing a novel water-splitting technology. | $22M / Series A / Dec 01, 2020 | ||
| WELL Health Technologies is the owner and operator of a portfolio of Primary Healthcare facilities. WELL Health Technologies is leveraging disruptive trends in the health and wellness space by strategically pursuing a proven blueprint M&A strategy in order to maximize profitable growth in the space. Target acquisition companies will be acrossvarious vertical industries within the health and wellness space and will possess low capital requirements and a high potential to exploit shifts in health trends. | $17.6M / Post-IPO Equity / Sep 01, 2020 | ||
| WELL Health Technologies is the owner and operator of a portfolio of Primary Healthcare facilities. WELL Health Technologies is leveraging disruptive trends in the health and wellness space by strategically pursuing a proven blueprint M&A strategy in order to maximize profitable growth in the space. Target acquisition companies will be acrossvarious vertical industries within the health and wellness space and will possess low capital requirements and a high potential to exploit shifts in health trends. | $7.9M / Post-IPO Debt / Mar 16, 2020 | ||
| MioTech is an artificial intelligence platform that empowers investment managers to better serve their clients in a world of complex data. By integrating and analyzing data from all types of sources, MioTech streamlines the entire investment process, creating an ultimate data-driven investing experience. MioTech has offices in Shanghai and HongKong.MioTech is backed by Horizons Ventures, ZhenFund, and prestigious individual investors around the world. | Series A / Jan 06, 2020 | ||
| Demetrix manufactures natural medicines using synthesis biology. The company uses genetics and computing enabled deciphering technology to produce drugs. It enables refactoring biotechnology microbial hosts for gene synthesis. The company engineers strain to produce co-evolved and bio-inspired medicines and nutraceuticals.The company was foundedin 2015 and is headquartered in Emeryville, California. | $50M / Series A / Jul 11, 2019 | ||
| Owlstone Medical focuses on creating breath-based diagnostic tools to enhance early detection of diseases such as cancer and respiratory conditions. The company's Breath Biopsy platform utilizes advanced technology to identify volatile organic compounds in breath, facilitating the discovery of non-invasive biomarkers. | $35M / Venture - Series Unknown / Oct 01, 2018 | ||
| See all 27 investments → | |||
Co-Investors
About Horizons Ventures
Horizons Ventures provides investment capital to companies developing technology-driven products across sectors such as digital services, artificial intelligence, and life sciences. The firm focuses on early and growth-stage businesses and supports them through funding and strategic guidance. Its portfolio includes companies working on software platforms, consumer applications, and scientific innovations. Horizons Ventures engages with founders to help shape business direction and scale operations. The firm also evaluates emerging technologies and market trends to guide its investment activities.
Horizons Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bart Swanson
Advisor
|
|||
Chris Liu
Special Projects
|
|||
Patrick Poon
Project Director
|
|||
Debbie Chang
Founder
|
|||
Frances Kang
Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Li Ka-shing invest in?
Li Ka-shing invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A and Series B stage. Most of the 27 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Li Ka-shing invest in?
Li Ka-shing typically joins rounds of $300k–$11M at Seed, $20M–$50M at Series A and $15M–$50M at Series B. These are whole funding-round sizes, not Li Ka-shing's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Li Ka-shing took part in.
How do I contact Li Ka-shing?
Public channels for Li Ka-shing include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Li Ka-shing last invest?
The most recent investment recorded for Li Ka-shing closed in Jan 2024. Shizune tracks 27 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
